<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787901</url>
  </required_header>
  <id_info>
    <org_study_id>EFRE Vitrification Trial</org_study_id>
    <nct_id>NCT03787901</nct_id>
  </id_info>
  <brief_title>Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast</brief_title>
  <official_title>The Ongoing Pregnancy Rate for Vitrification of Day-4 Morula and Day-5 Blastocyst</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Foundation of Reproductive Endocrinology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Al Hayat ICSI Centre of Alexandria, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agial IVF/ICSI Unit of Alexandria, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Al Madina Fertility centre of Alexandria, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rahem Fertility Center of Zagazig, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IbnSina IVF Centre of Sohag, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bannon IVF Centre of Assiut, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quena IVF Centre of Quena, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alrahma Fertility Hospital of Sohag, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alnada Fertility Center of Bniswaif, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alhayat Algaded IVF Centre of Mansoura, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ganna Fertility Hospital of Cairo, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Egyptian Foundation of Reproductive Endocrinology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the vitrification at Day-4 (morula stage) with the blastocyst stage vitrification
      outcomes with the transfer of all day 5 after warming seems need evaluation. To the best of
      our knowledge, there has been no random-controlled trial conducted such comparison.
      Altogether, this trial is to evaluate the morula stage vitrification to blastocyst
      vitrification on the ongoing pregnancy rate after ICSI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitrification of human embryos has been a paradigm-shifting procedure for higher survival
      rate compared with the slow freezing protocol. The evidence is scarce to support superior
      results for vitrifying certain stages of preimplantation embryos. Anecdotal evidence suggests
      that blastocyst vitrification is more forgiving than cleavage stages. However, data obtained
      from the procedure of assisted shrinkage of blastocysts before vitrification show a higher
      survival rate, suggesting that fluid accumulation insides the blastocyst can be a barrier for
      cryoprotectant to reach the cells. Although reassuring, whether facilitating the
      cryoprotectants transfer to cells by the laser-assisted shrinkage or other modalities is
      completely safe remains elusive. Moreover, other claims compare between day-3 embryos
      vitrification and blastocyst stage, suggesting no difference exists.

      One of the most critical stages in embryo development is the maternal to zygotic genome
      activation (MZA), which occurs at the 4 to 8 cell stages. Therefore, it seems the morula
      stage is still cleavage but passed the MZA. Morula in the most grading system has compaction
      for all or the majority of cells so if vitrified, the morula stage can bypass the earlier
      stage of vitrification as well as the need for the artificial shrinkage for blastocyst stage.
      Therefore, comparing the vitrification at Day-4 (morula stage) with the blastocyst stage
      vitrification outcomes with the transfer of all day 5 after warming seems need evaluation. To
      the best of our knowledge, there has been no random-controlled trial conducted such
      comparison. Altogether, this trial is to evaluate the morula stage vitrification to
      blastocyst vitrification on the ongoing pregnancy rate after ICSI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ongoing pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Continued pregnancy at &gt; gestational week 12 or more per initiated cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>14 days</time_frame>
    <description>positive b-hCG at ≥ 14 days following embryo transfer per initiated cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sacs with a heartbeat on ultrasound per embryo transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative implantation rate</measure>
    <time_frame>One year</time_frame>
    <description>Sacs with a heartbeat on ultrasound per embryo transferred within one year from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>7 weeks</time_frame>
    <description>Sacs with a positive heartbeat on ultrasound at ≥ 7 weeks of gestation per initiated cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative clinical pregnancy rate</measure>
    <time_frame>One year</time_frame>
    <description>Sacs with a positive heartbeat on ultrasound at ≥ 7 weeks of gestation per initiated cycle within one year from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative ongoing pregnancy rate</measure>
    <time_frame>One year</time_frame>
    <description>continued pregnancy after gestational week 12 per initiated cycle within one year from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Twin pregnancy rate</measure>
    <time_frame>One year</time_frame>
    <description>≥ two foetuses with a heartbeat per initiated cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo survival rate after thawing</measure>
    <time_frame>Five days of culture</time_frame>
    <description>Blastocyst re-expansion for day 5 vitrified embryo after two hours and blastocyst formation on day 5 for embryo vitrified on day 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1120</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Morula Vitrification Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst Vitrification Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morula Vitrification</intervention_name>
    <description>Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.</description>
    <arm_group_label>Blastocyst Vitrification Arm</arm_group_label>
    <arm_group_label>Morula Vitrification Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women age of ≥ 18 to ≤ 40

          2. BMI of ≤ 31

          3. Normal responder (≥ 12 antral follicle count (AFC) during basal ultrasound
             examination) or hyper responder

          4. The freeze-all groups including PCOS, OHSS, or high Progesterone at trigger day

          5. Women who have ≥ 1 year of primary or secondary infertility

          6. Tubal factor (unilateral, bilateral obstruction or salpingectomy)

          7. Fresh semen ejaculates but not frozen or surgically retrieved sperm

          8. Male factor: oligoasthenozoospermia but not globozoospermia or pinhead sperm

          9. Women who are undergoing their first or second ICSI attempts with a previously
             successful attempt

         10. Women who undergo only freeze-all embryo

         11. Freeze-all for poor endometrium at the fresh cycle

         12. Freeze-all due to abnormal endometrial findings such as polyp or myoma with a decision
             for freeze all for surgical correction.

         13. Women who have normal endometrial thickness (≥ 8) and echo-pattern at the time of
             progesterone start in the proposed vitrified warmed cycle

        Exclusion Criteria:

          1. Women who have uncorrectable uterine pathology or abnormality including submucous
             myoma

          2. Women or their husbands who have abnormal karyotyping

          3. Women with a history of recurrent abortions or repeated implantation failures

          4. Women who have uncontrolled diabetes

          5. Women with diagnosed or undiagnosed liver or renal disease

          6. Women who had a history of malignancy or borderline pathology

          7. Women who will not meet the inclusion criteria

          8. Women who will refuse to participate in the study

          9. Women with endometriosis

         10. Patient undergoing PGS or PGD

         11. Surgically retrieved, frozen-thawed and pinpoint sperm or globozoospermia

         12. Adenomyosis

         13. Severe medical condition
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Agial</name>
      <address>
        <city>Alexandria</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisham Saleh, MD</last_name>
      <phone>+201223152272</phone>
      <email>hishamalisaleh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hisham Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Al Hayat ICSI Centre of Alexandria</name>
      <address>
        <city>Alexandria</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Maghraby, MD</last_name>
      <phone>+201222137317</phone>
      <email>hassanmaghraby@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dalal AlGaziry, MD</last_name>
      <phone>+201222137317</phone>
      <email>hassanmaghraby@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hassan Maghraby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalal AlGaziry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AlMadina IVF and ICSI Centre</name>
      <address>
        <city>Alexandria</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf Aboali, MD</last_name>
      <phone>+201007333950</phone>
      <email>aboalimadina@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ashraf Aboali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bannon IVF Centre</name>
      <address>
        <city>Assiut</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai Emad, BSc</last_name>
      <phone>+201094845310</phone>
      <email>mai_emad_khedr@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mai Emad, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AlNada Fertility Centre of Baniswaif</name>
      <address>
        <city>Baniswaif</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed A Youssif</last_name>
      <phone>+20114 8088826</phone>
      <email>m.a.youssef@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Mohamed A Youssif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Momen Abdelkhalik, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ganaa IVF Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Hady, Lab Director</last_name>
      <phone>+20111768111</phone>
      <email>hady_zam@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alhayat Algaded IVF Centre</name>
      <address>
        <city>Mansoura</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Gibreel, MD</last_name>
      <phone>+20 100 404 5733</phone>
      <email>ahmedfathgi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed Gibreel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quena Fertilty Centre</name>
      <address>
        <city>Quena</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Mowafy, MD</last_name>
      <phone>+201005688230</phone>
      <email>ahm.mowafy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed Mowafy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALRahma Fertilty Hospital</name>
      <address>
        <city>Sohag</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed y AbdelRahman</last_name>
      <phone>+20100 7575474</phone>
      <email>Dryahyaz@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Y AbdelRahman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IbnSina IVF Centre</name>
      <address>
        <city>Sohag</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Fawzy, MD</last_name>
      <phone>+201011122286</phone>
      <email>drfawzy001@me.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Fawzy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Alaa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rahem Fertility Centre of Zagazig</name>
      <address>
        <city>Zagazig</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eman Elgendy, MD</last_name>
      <phone>+2-1227491143</phone>
      <email>Eman_elgindy2013@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Eman Elgendy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Egyptian Foundation of Reproductive Endocrinology</investigator_affiliation>
    <investigator_full_name>Hassan Maghraby</investigator_full_name>
    <investigator_title>MD, Director, Al Hayat ICSI Centre of Alexandria, Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

